The Breast
Volume 20, Issue 6 , Pages 491-494 , December 2011

FDG-PET/CT in the staging of local/regional metastases in breast cancer

Received 8 February 2011 ,Revised 26 April 2011 ,Accepted 3 July 2011.

References 

  1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001;2:133–140
  2. Rampaul RS, Pinder SE, Elston CW, Ellis IO. Prognostic and predictive factors in primary breast cancer and their role in patient management: the Nottingham Breast Team. Eur J Surg Oncol. 2001;27:229–238
  3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1997;47:5–27
  4. National Cancer Institute. U.S. National Institutes of Health. 2010;www.cancer.gov
  5. Cancer Research UK. info.cancerresearchuk.org. 2008.
  6. Saez RA, McGuire WL, Clark GM. Prognostic factors in breast cancer. Semin Surg Oncol. 1989;5:102–110
  7. HSr Cody. Current surgical management of breast cancer. Curr Opin Obstet Gynecol. 2002;14:45–52
  8. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000;88:2540–2545
  9. Kuehn T, Bembenek A, Decker T, Sautter-Bihl ML, Untch M, Wallwiener D, et al. A concept for the clinical implementation of sentinel lymph node biopsy in patients with breast carcinoma with special regard to quality assurance. Cancer. 2005;103:451–461
  10. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or = 5 cm) invasive breast cancer. Ann Surg Oncol. 2001;8:688–692
  11. Schwartz GF. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J. 2004;10:85–88
  12. Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–7720
  13. Specht MC, Fey JV, Borgen PI, HSr Cody. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?. J Am Coll Surg. 2005;200:10–14
  14. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging?. J Clin Oncol. 2008;26:712–720
  15. Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473–478
  16. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol. 2004;22:277–285
  17. Weir L, Worsley D, Bernstein V. The value of FDG positron emission tomography in the management of patients with breast cancer. Breast J. 2005;11:204–209
  18. Heusner TA, Kuemmel S, Hahn S, Koeninger A, Otterbach F, Hamami ME, et al. Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients. Eur J Nucl Med Mol Imaging. 2009;36:1543–1550
  19. Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;8:165
  20. Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg. 2009;33:943–949
  21. Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–4751
  22. Jager JJ, Keymeulen K, Beets-Tan RG, Hupperets P, van Kroonenburgh M, Houben R, et al. FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: a pilot study. Acta Oncol. 2010;49:185–191
  23. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Yen RF. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res. 2000;20:2189–2192
  24. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK, Dunnwald LK, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics. 2002;22:5–17
  25. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit. 2007;13:RA37–46

PII: S0960-9776(11)00138-X

doi: 10.1016/j.breast.2011.07.002

The Breast
Volume 20, Issue 6 , Pages 491-494 , December 2011

Article Tools